Premium
Non‐viral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome)
Author(s) -
Tomanin R,
Friso A,
Alba S,
Puicher E Piller,
Mennuni C,
Monica N La,
Hortelano G,
Zacchello F,
Scarpa M
Publication year - 2002
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2002.tb03119.x
Subject(s) - mucopolysaccharidosis type ii , genetic enhancement , enzyme replacement therapy , hunter syndrome , viral vector , medicine , cell culture , fibroblast , heterologous , transplantation , cell therapy , microbiology and biotechnology , cell , virology , biology , gene , biochemistry , disease , genetics , recombinant dna
Aims : Hunter syndrome is a rare X‐linked lysosomal storage disorder caused by the deficiency of the housekeeping enzyme iduronate‐2‐sulphatase (IDS). Deficiency of IDS causes accumulation of undegraded dermatan and heparan‐sulphate in various tissues and organs. Approaches have been proposed for the symptomatic therapy of the disease, including bone marrow transplantation and, very recently, enzyme replacement. To date, gene therapy strategies have considered mainly retroviral and adenoviral transduction of the correct cDNA. In this paper, two non‐viral somatic gene therapy approaches are proposed: encapsulated heterologous cells and muscle electro‐gene transfer (EGT). Methods : Hunter primary fibroblasts were co‐cultured with either cell clones over‐expressing the lacking enzyme or with the same incorporated in alginate microcapsules. For EGT, plasmid vector was injected into mouse quadriceps muscle, which was then immediately electro‐stimulated. Results : Co‐culturing Hunter primary fibroblasts with cells over‐expressing IDS resulted in a three‐ to fourfold increase in fibroblast enzyme activity with respect to control cells. Fibroblast IDS activity was also increased after co‐culture with encapsulated cells. EGT was able to transduce genes in mouse muscle, resulting in at least a tenfold increase in IDS activity 1–5 weeks after treatment. Conclusion : Although preliminary, results from encapsulated heterologous cell clones and muscle EGT encourage further evaluations for possible application to gene therapy for Hunter syndrome.